← All countries · Europe
95%
MCV1
2025 · WHO/UNICEF estimate
95%
DTP3
2025 · WHO/UNICEF estimate
95%
IPV complete
2025 · WHO/UNICEF estimate
85%
HepB3
2025 · WHO/UNICEF estimate
51
Measles cases
2025 reported
3,950
Pertussis (whooping cough) cases
2018 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | —% · Administrative (country-reported) | — | too few points | D · poor |
| DTP1First dose of diphtheria-tetanus-pertussis | 97%2025 · WHO/UNICEF estimate | 97% | A · strong | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 95%2025 · WHO/UNICEF estimate | 95% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 97%2025 · WHO/UNICEF estimate | 97% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | 95%2025 · WHO/UNICEF estimate | 95% | C · weak | |
| MCV1First dose of measles-containing vaccine | 95%2025 · WHO/UNICEF estimate | 95% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 92%2025 · WHO/UNICEF estimate | 92% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 95%2025 · WHO/UNICEF estimate | 95% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 85%2025 · WHO/UNICEF estimate | 85% | B · good | |
| HepB birthHepatitis B birth dose within 24 hours | —% · Administrative (country-reported) | — | too few points | no data |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 95%2025 · WHO/UNICEF estimate | 95% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 93%2025 · Administrative (country-reported) | 93% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 92%2025 · WHO/UNICEF estimate | 92% | A · strong | |
| RotaCRotavirus vaccine, complete series | 10%2025 · WHO/UNICEF estimate | 10% | C · weak | |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | 81.7%2020 · Administrative (country-reported) | 81.7% | too few points | D · poor |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 77%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 71%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 64%2025 · WHO/UNICEF estimate | — | C · weak |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 512025 | 5.7per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | C · weak | |
| Mumps all countries · vaccine evidence | 1402011 | 17.7per 1,000,000 total population | no data | |
| Pertussis (whooping cough) all countries · vaccine evidence | 3,9502018 | 463.8per 1,000,000 total population | D · poor | |
| Diphtheria all countries · vaccine evidence | 242025 | 2.7per 1,000,000 total population | B · good | |
| Tetanus (total) all countries · vaccine evidence | 12023 | 0.1per 1,000,000 total population | D · poor | |
| Neonatal tetanus all countries · vaccine evidence | 12023 | 0per 1,000 live births | D · poor | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Japanese encephalitis all countries · vaccine evidence | 02009 | 0per 1,000,000 total population | no data | |
| Invasive meningococcal disease all countries · vaccine evidence | 392025 | 4.3per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 442024 | 4.9per 1,000,000 total population | C · weak |
National schedule (latest WHO listing)
Show the schedule (67 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| COVID19COVID-19 vaccine | 1 | Adults | All older adults | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions | |
| DENGUEDengue vaccine | 1 | Risk group(s) | ||
| DTAPDTaP (acellular) vaccine | 5 | Y11-Y15 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | M2 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 2 | M4 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 3 | M12 | General/routine | |
| DTAPIPVDTaP-IPV (acellular) vaccine | 4 | Y4-Y7 | General/routine | |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 1 | >=Y1 | Risk group(s) | |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 2 | +M6 | Risk group(s) | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Y11-Y15 | General/routine | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M6 | General/routine | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | Risk group(s) | if mother is HBA1c-pos |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | Y11-Y14 | HPV administered to females and males | Females and males |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 2 | +M6 | HPV administered to females and males | Females and males |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >=Y65 | Adults | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| JE_INACTDJE-Inact (Japanese Encephalitis inactivated) vaccine | 1 | Travellers | Travellers only | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | M24 | General/routine | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 2 | Y11-Y15 | General/routine | |
| MEN_BMeningococcal B vaccine | 1 | M3 | General/routine | |
| MEN_BMeningococcal B vaccine | 2 | M5 | General/routine | |
| MEN_BMeningococcal B vaccine | 3 | M12-M18 | General/routine | |
| MEN_BMeningococcal B vaccine | 4 | Y11-Y15 | General/routine | |
| MEN_BMeningococcal B vaccine | 5 | Y11-Y15 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M9 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | M12 | General/routine | |
| MMRVMMRV (Measles, mumps, rubella and varicella) vaccine | 1 | M9 | General/routine | Babies |
| MMRVMMRV (Measles, mumps, rubella and varicella) vaccine | 2 | M12 | General/routine | Babies |
| MPOXMpox (monkeypox) vaccine | 1 | >=Y18 | Risk group(s) | The vaccination (2 doses) is recommended for occupational indications, MSM and transgender people with multiple sexual partners. A booster vaccination is currently recommended 2 years after the second dose if the person continues to be at high risk of exposure. |
| MPOXMpox (monkeypox) vaccine | 2 | +D28 | Risk group(s) | The vaccination (2 doses) is recommended for occupational indications, MSM and transgender people with multiple sexual partners. A booster vaccination is currently recommended 2 years after the second dose if the person continues to be at high risk of exposure. |
| MPOXMpox (monkeypox) vaccine | 3 | +Y2 | Risk group(s) | The vaccination (2 doses) is recommended for occupational indications, MSM and transgender people with multiple sexual partners. A booster vaccination is currently recommended 2 years after the second dose if the person continues to be at high risk of exposure. |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | M2 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 2 | M4 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 3 | M12 | General/routine | |
| RABIESRabies vaccine | 1 | >=Y0 | Risk group(s) | |
| RABIESRabies vaccine | 2 | +D28 | Risk group(s) | |
| RABIESRabies vaccine | 3 | +Y1 | Risk group(s) | |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 1 | M2 | General/routine | |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 2 | M4 | General/routine | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Adults | Older adults | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Pregnant women | Pregnant women | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Risk group(s) | People with chronic conditions | |
| RSV_MONORSV (Respiratory syncytial virus) monoclonal antibodies | 1 | M0-M23 | General/routine | Newborns |
| TBE_ADULTAdult TBE (tick borne encephalitis) vaccine | 1 | 1st contact | Risk group(s) · SUBNATIONAL | |
| TBE_ADULTAdult TBE (tick borne encephalitis) vaccine | 2 | +M1-M3 | Risk group(s) · SUBNATIONAL | |
| TBE_ADULTAdult TBE (tick borne encephalitis) vaccine | 3 | +M5-M12 | Risk group(s) · SUBNATIONAL | |
| TBE_ADULTAdult TBE (tick borne encephalitis) vaccine | 4 | +Y10 | Risk group(s) · SUBNATIONAL | |
| TBE_ADULTAdult TBE (tick borne encephalitis) vaccine | 5 | +Y10 | Risk group(s) · SUBNATIONAL | |
| TBE_ADULTAdult TBE (tick borne encephalitis) vaccine | 6 | +Y10 | Risk group(s) · SUBNATIONAL | |
| TBE_PEDIATRICPediatric TBE (tick borne encephalitis) vaccine | 1 | >=Y3 | Risk group(s) · SUBNATIONAL | All persons who are regularly in forested areas, except in Geneva and Ticino Cantons |
| TBE_PEDIATRICPediatric TBE (tick borne encephalitis) vaccine | 2 | +M1-M3 | Risk group(s) · SUBNATIONAL | All persons who are regularly in forested areas, except in Geneva and Ticino Cantons |
| TBE_PEDIATRICPediatric TBE (tick borne encephalitis) vaccine | 3 | +M5-M12 | Risk group(s) · SUBNATIONAL | All persons who are regularly in forested areas, except in Geneva and Ticino Cantons |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | Y25 | Adults | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | Y45 | Adults | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | Y65 | Adults | |
| VARICELLAVaricella vaccine | 1 | M9 | General/routine | |
| VARICELLAVaricella vaccine | 2 | M12 | General/routine | |
| YFYF (Yellow fever) vaccine | 1 | Travellers | Travellers | |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 1 | >=Y65 | Adults | All persons Y65+, Immunocompromised persons from age 50Y, and severely immunocompromised persons from age 18+ |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 1 | 1st contact | Risk group(s) | All persons Y65+, Immunocompromised persons from age 50Y, and severely immunocompromised persons from age 18+ |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 2 | +M2 | Adults | All persons Y65+, Immunocompromised persons from age 50Y, and severely immunocompromised persons from age 18+ |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 2 | +M2 | Risk group(s) | All persons Y65+, Immunocompromised persons from age 50Y, and severely immunocompromised persons from age 18+ |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.